A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk
; 21(2): 113-118, 2021 02.
Article
en En
| MEDLINE
| ID: mdl-33422470
ABSTRACT
INTRODUCTION:
Adults with acute myeloid leukemia (AML) have a high rate of remission; however, more than 50% relapse. C-kit is expressed in approximately 60% of patients with de novo AML and represents a potential therapeutic target. MATERIALS ANDMETHODS:
Patients with newly diagnosed AML received 12 months of imatinib mesylate as maintenance therapy after the completion of post-remission therapy. The primary objective was to determine whether this approach improved progression-free survival (defined as no relapse and no death) compared with historical controls.RESULTS:
The median progression-free survival of patients < 60 years of age was 52.1 months (historical control, 13 months) and for patients ≥ 60 years of age was 10.7 months (historical control, 8 months). The median level of AF1q expression was high (9.59), and 84% of patients had moderate or high levels of drug-resistance factors.CONCLUSIONS:
Imatinib maintenance therapy may improve the outcome of newly diagnosed patients with AML who are < 60 years of age.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Leucemia Mieloide Aguda
/
Proteínas Proto-Oncogénicas c-kit
/
Inhibidores de Proteínas Quinasas
/
Mesilato de Imatinib
/
Recurrencia Local de Neoplasia
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Idioma:
En
Revista:
Clin Lymphoma Myeloma Leuk
Asunto de la revista:
NEOPLASIAS
Año:
2021
Tipo del documento:
Article